Last reviewed · How we verify
Risperidone high dose
Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood.
Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors in the brain to reduce psychotic symptoms and stabilize mood. Used for Schizophrenia, Bipolar I disorder (acute mania and maintenance), Irritability associated with autism spectrum disorder.
At a glance
| Generic name | Risperidone high dose |
|---|---|
| Sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor; Serotonin 5-HT2A receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry/Neurology |
| Phase | FDA-approved |
Mechanism of action
Risperidone is an atypical antipsychotic that antagonizes dopamine D2 receptors in the mesolimbic and mesocortical pathways, reducing positive symptoms of psychosis such as hallucinations and delusions. It also blocks serotonin 5-HT2A receptors, which contributes to its efficacy in treating negative symptoms and mood disturbances. At higher doses, it provides more potent dopamine antagonism, making it suitable for treatment-resistant psychotic disorders.
Approved indications
- Schizophrenia
- Bipolar I disorder (acute mania and maintenance)
- Irritability associated with autism spectrum disorder
- Treatment-resistant psychosis (at higher doses)
Common side effects
- Extrapyramidal symptoms (tremor, rigidity, akathisia)
- Weight gain
- Hyperprolactinemia
- Sedation
- Orthostatic hypotension
- Metabolic syndrome
- QT prolongation
Key clinical trials
- Subjective Experience Following Psilocybin (PHASE2)
- Study of a Novel Antipsychotic ITI-007 in Schizophrenia (PHASE2)
- High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone (PHASE4)
- Multidisciplinary Design to Optimize Schizophrenia Treatment Based on Multi-omics Data and Systems Biology Analysis (PHASE4)
- Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction (NA)
- Optimizing and Individualizing the Pharmacological Treatment of First-episode Schizophrenic Patients
- Insight Enhancement Program vs. Metacognitive Training for Psychosis in Patients With Schizophrenia: A Three-Armed Comparative Randomized Controlled Trial (PHASE3)
- European Long-acting Antipsychotics in Schizophrenia Trial (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: